Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy.

Álvarez-Lerma F, Rodriguez M, Soriano MC, Catalán M, Llorente AM, Vidart N, Garitacelaya M, Maravi E, Fernández Rey E, Alvarado F, López-Sánchez M, Alvarez-Sánchez B, Granado D, Quintana E; Study Group of Liposomal Amphotericin B in the ICU..

Rev Esp Quimioter. 2013 Dec;26(4):360-8.

2.

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, Brennan DM, Koenig W, Jukema JW, Nambi V, Wright RS, Menon V, Lincoff AM, Nissen SE; VISTA-16 Investigators..

JAMA. 2014 Jan 15;311(3):252-62. doi: 10.1001/jama.2013.282836.

PMID:
24247616
3.

Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.

Alvarez-Lerma F, Soriano MC, Rodríguez M, Catalán M, Llorente AM, Vidart N, Garitacelaya M, Maraví E, Fernández E, Alvarado F, López M, Alvarez-Sánchez B, Espinosa J, Quintana E; Study Group of Liposomal Amphotericin B in the ICU..

Rev Esp Quimioter. 2012 Sep;25(3):206-15.

4.

Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators..

N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13.

Supplemental Content

Loading ...
Support Center